Serum neurofilament light chain as a preclinical marker of neurodegeneration
Abstract
To date, most clinical trials of disease-modifying drugs for neurodegenerative diseases, namely Alzheimer's disease, have been unsuccessful, mainly due to the inclusion of patients with too advanced disease. 1 Honig LS Vellas B Woodward M et al. Trial of solanezumab for mild dementia due to Alzheimer's Disease. N Engl J Med. 2018; 378: 321-330 Crossref PubMed Scopus (565) Google Scholar One explanation is that, once the pathophysiological...
Paper Details
Title
Serum neurofilament light chain as a preclinical marker of neurodegeneration
Published Date
Dec 1, 2019
Journal
Volume
18
Issue
12
Pages
1070 - 1071
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History